Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling

Yan G. Ni, Kambeez Berenji, Na Wang, Misook Oh, Nita Sachan, Asim Dey, Jun Cheng, Guangrong Lu, David J. Morris, Diego H Castrillon, Robert D. Gerard, Beverly A Rothermel, Joseph A Hill

Research output: Contribution to journalArticle

193 Scopus citations

Abstract

BACKGROUND - Cellular hypertrophy requires coordinated regulation of progrowth and antigrowth mechanisms. In cultured neonatal cardiomyocytes, Foxo transcription factors trigger an atrophy-related gene program that counters hypertrophic growth. However, downstream molecular events are not yet well defined. METHODS AND RESULTS - Here, we report that expression of either Foxo1 or Foxo3 in cardiomyocytes attenuates calcineurin phosphatase activity and inhibits agonist-induced hypertrophic growth. Consistent with these results, Foxo proteins decrease calcineurin phosphatase activity and repress both basal and hypertrophic agonist-induced expression of MCIP1.4, a direct downstream target of the calcineurin/NFAT pathway. Furthermore, hearts from Foxo3-null mice exhibit increased MCIP1.4 abundance and a hypertrophic phenotype with normal systolic function at baseline. Together, these results suggest that Foxo proteins repress cardiac growth at least in part through inhibition of the calcineurin/NFAT pathway. Given that hypertrophic growth of the heart occurs in multiple contexts, our findings also suggest that certain hypertrophic signals are capable of overriding the antigrowth program induced by Foxo. Consistent with this, multiple hypertrophic agonists triggered inactivation of Foxo proteins in cardiomyocytes through a mechanism requiring the PI3K/Akt pathway. In addition, both Foxo1 and Foxo3 are phosphorylated and consequently inactivated in hearts undergoing hypertrophic growth induced by hemodynamic stress. CONCLUSIONS - This study suggests that inhibition of the calcineurin/NFAT signaling cascade by Foxo and release of this repressive action by the PI3K/Akt pathway are important mechanisms whereby Foxo factors govern cell growth in the heart.

Original languageEnglish (US)
Pages (from-to)1159-1168
Number of pages10
JournalCirculation
Volume114
Issue number11
DOIs
StatePublished - Sep 1 2006

Keywords

  • Angiotensin
  • Calcineurin
  • Hypertrophy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling'. Together they form a unique fingerprint.

  • Cite this

    Ni, Y. G., Berenji, K., Wang, N., Oh, M., Sachan, N., Dey, A., Cheng, J., Lu, G., Morris, D. J., Castrillon, D. H., Gerard, R. D., Rothermel, B. A., & Hill, J. A. (2006). Foxo transcription factors blunt cardiac hypertrophy by inhibiting calcineurin signaling. Circulation, 114(11), 1159-1168. https://doi.org/10.1161/CIRCULATIONAHA.106.637124